DDInter1702 DDInter596
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myeloma, sarcoma, and pediatric cancers.[A1573,A257614,L45231] However, one of the major side effects of doxorubicin is cardiotoxicity, which excludes patients with poor heart function and requires treatment termination once the maximally tolerated cumulative dose is reached.
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Sorafenib {u} (Compound) treats {v} (Disease) thyroid cancer
thyroid cancer {u} (Disease) is treated by {v} (Compound) Doxorubicin
Sorafenib {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Doxorubicin
Sorafenib {u} (Compound) upregulates {v} (Gene) P4HA2
P4HA2 {u} (Gene) is upregulated by {v} (Compound) Doxorubicin
Sorafenib {u} (Compound) downregulates {v} (Gene) FAM20B
FAM20B {u} (Gene) is upregulated by {v} (Compound) Doxorubicin
Sorafenib {u} (Compound) binds {v} (Gene) STK10
STK10 {u} (Gene) is upregulated by {v} (Compound) Doxorubicin
Sorafenib {u} (Compound) upregulates {v} (Gene) XBP1
XBP1 {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Sorafenib {u} (Compound) downregulates {v} (Gene) CCNA2
CCNA2 {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Sorafenib {u} (Compound) binds {v} (Gene) CDK7
CDK7 {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Sorafenib {u} (Compound) causes {v} (Side Effect) Infestation NOS
Infestation NOS {u} (Side Effect) is caused by {v} (Compound) Doxorubicin
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Sorafenib (Compound) treats thyroid cancer (Disease) and thyroid cancer (Disease) is treated by Doxorubicin (Compound)
Sorafenib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Doxorubicin (Compound)
Sorafenib (Compound) upregulates P4HA2 (Gene) and P4HA2 (Gene) is upregulated by Doxorubicin (Compound)
Sorafenib (Compound) downregulates FAM20B (Gene) and FAM20B (Gene) is upregulated by Doxorubicin (Compound)
Sorafenib (Compound) binds STK10 (Gene) and STK10 (Gene) is upregulated by Doxorubicin (Compound)
Sorafenib (Compound) upregulates XBP1 (Gene) and XBP1 (Gene) is downregulated by Doxorubicin (Compound)
Sorafenib (Compound) downregulates CCNA2 (Gene) and CCNA2 (Gene) is downregulated by Doxorubicin (Compound)
Sorafenib (Compound) binds CDK7 (Gene) and CDK7 (Gene) is downregulated by Doxorubicin (Compound)
Sorafenib (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Doxorubicin (Compound)